Integral Diagnostics Ltd. (AU:IDX)
ASX:IDX
Want to see AU:IDX full AI Analyst Report?
IDX Stock Chart & Stats
AU$2.26
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.26
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$2.00 - AU$3.07
Previous CloseN/A
Volume920.11K
Average Volume (3M)911.20K
Market Cap
AU$809.09M
Enterprise ValueAU$1.62B
Total Cash (Recent Filing)AU$34.12M
Total Debt (Recent Filing)AU$841.54M
Price to Earnings (P/E)57.7
Beta0.53
Next Earnings
Aug 25, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend Yield2.65%
Share Statistics
EPS (TTM)0.03
Shares Outstanding373,066,530
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.57
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.94Price Target Upside30.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.13
Revenue Forecast (FY)AU$801.34M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth of ~27.7% indicates expanding patient volumes and service penetration across community and hospital settings. Durable demand for diagnostic imaging and fixed-cost leverage can drive continued top-line expansion and support investment in capacity over the next 2–6 months.
High Gross MarginA gross margin above 95% reflects strong pricing and operational efficiency in imaging and reporting services. High gross margins provide structural buffer to absorb SG&A and reimbursement pressures, supporting margin sustainability if throughput and modality mix remain stable.
Improved LeverageAn improved debt-to-equity near 0.84 signals better capital structure and reduced financial risk compared with prior periods. Lower leverage enhances capacity for targeted capital expenditure, clinic expansion or bolt-on acquisitions, strengthening long-term market position and operational resilience.
Bears Say
Very Low Net Profit MarginDespite strong revenues and high gross margins, a net margin under 1% shows limited ability to convert sales into shareholder earnings. Persistent low net profitability suggests structural cost pressures or high overhead that could constrain reinvestment, dividend capacity and long‑term returns.
Declining Free Cash FlowA near 59% drop in free cash flow materially weakens cash generation despite positive operating cash flow. Reduced FCF limits funding for maintenance capex, debt repayment or acquisitions and raises liquidity risk if the trend persists, undermining financial flexibility over months ahead.
Low Return On EquityROE below 1% indicates the company is not translating asset and equity base into meaningful shareholder returns. This suggests inefficiencies in capital allocation or elevated non-operating costs and may impair long-term investor confidence and ability to attract capital for growth.
Integral Diagnostics Ltd. News
IDX FAQ
What was Integral Diagnostics Ltd.’s price range in the past 12 months?
Integral Diagnostics Ltd. lowest share price was AU$2.00 and its highest was AU$3.07 in the past 12 months.
What is Integral Diagnostics Ltd.’s market cap?
Integral Diagnostics Ltd.’s market cap is AU$809.09M.
When is Integral Diagnostics Ltd.’s upcoming earnings report date?
Integral Diagnostics Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 85 days.
How were Integral Diagnostics Ltd.’s earnings last quarter?
Integral Diagnostics Ltd. released its earnings results on Feb 23, 2026. The company reported AU$0.024 earnings per share for the quarter, missing the consensus estimate of AU$0.056 by -AU$0.032.
Is Integral Diagnostics Ltd. overvalued?
According to Wall Street analysts Integral Diagnostics Ltd.’s price is currently Undervalued.
Does Integral Diagnostics Ltd. pay dividends?
Integral Diagnostics Ltd. pays a Semiannually dividend of AU$0.04 which represents an annual dividend yield of 2.65%. See more information on Integral Diagnostics Ltd. dividends here
What is Integral Diagnostics Ltd.’s EPS estimate?
Integral Diagnostics Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Integral Diagnostics Ltd. have?
Integral Diagnostics Ltd. has 373,066,530 shares outstanding.
What happened to Integral Diagnostics Ltd.’s price movement after its last earnings report?
Integral Diagnostics Ltd. reported an EPS of AU$0.024 in its last earnings report, missing expectations of AU$0.056. Following the earnings report the stock price went down -5.83%.
Which hedge fund is a major shareholder of Integral Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:IDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integral Diagnostics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$2.94 (30.09% Upside)
AU$2.94 (30.09% Upside)
Blogger Sentiment
Bullish
AU:IDX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$170.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.34%
12-Months-Change
Fundamentals
Return on Equity
2.05%
Trailing 12-Months
Asset Growth
4.81%
Trailing 12-Months
Company Description
Integral Diagnostics Ltd.
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services through 67 radiology clinics. The company was incorporated in 2008 and is headquartered in Melbourne, Australia.
IDX Stock 12 Month Forecast
Average Price Target
AU$2.94
▲(30.09% Upside)
Technical Analysis
Healius Limited
―
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―
Options Prices
Currently, No data available
---